SCHEMBL15538388

SCHEMBL15538388

Cc1ccccc1[C@H](O)[C@@](C)(O)C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACP3 P15309 1/20 0.41
ESR1 P03372 1/20 0.38
KDM4E B2RXH2 1/20 0.38
LMNA P02545 1/20 0.38
ALDH1A1 P00352 2/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
GAA P10253 1/20 0.36
OPRM1 P35372 2/20 0.36
OPRD1 P41143 2/20 0.36
OPRK1 P41145 2/20 0.36
OPRL1 P41146 2/20 0.36
PDK1 Q15118 1/20 0.35
PDK2 Q15119 1/20 0.35
PDK3 Q15120 1/20 0.35
PDK4 Q16654 1/20 0.35
CTSA P10619 2/20 0.33
HPGD P15428 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
CYP1A2 P05177 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16795796 1.00 ACP3 (0.41) ACP3ESR1KDM4ELMNAALDH1A1
SCHEMBL28884524 1.00 ACP3 (0.41) ACP3ESR1KDM4ELMNAALDH1A1
SCHEMBL28364909 1.00 ACP3 (0.41) ACP3ESR1KDM4ELMNAALDH1A1
SCHEMBL15539624 1.00 ACP3 (0.41) ACP3ESR1KDM4ELMNAALDH1A1
SCHEMBL15539824 0.81 CYP2D6 (0.33) LMNAALDH1A1PDK1PDK2PDK3
SCHEMBL16795808 0.81 ADRB2 (0.45) ACP3ALDH1A1PDK1PDK2PDK3
SCHEMBL16795880 0.81 CYP2D6 (0.33) LMNAALDH1A1PDK1PDK2PDK3
SCHEMBL15540082 0.81 ADRB2 (0.45) ACP3ALDH1A1PDK1PDK2PDK3
SCHEMBL15539306 0.81 CES2 (0.45) ALDH1A1GAAPDK1PDK2PDK3
SCHEMBL28368995 0.81 CYP2D6 (0.33) LMNAALDH1A1PDK1PDK2PDK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11896593-B2 Sulfamate derivative compounds for use in treating or alleviating a psychiatric disorder BIO-PHARM SOLUTIONS CO., LTD. (KR) 2024-02-13 US disclosed
EP-4211125-A1 SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER Bio-Pharm Solutions Co., Ltd. (KR) 2023-07-19 EP disclosed
US-20220218702-A1 SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER BIO-PHARM SOLUTIONS CO., LTD. (KR) 2022-07-14 US disclosed
WO-2022054987-A1 SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER BIO-PHARM SOLUTIONS CO., LTD. (KR) 2022-03-17 WO disclosed
CN-106507667-B Sulfamate derivatives for the prevention or treatment of epilepsy 比皮艾思药物研发有限公司 2020-01-24 CN disclosed
EP-3443959-A1 SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING PAIN Bio-Pharm Solutions Co., Ltd. (KR) 2019-02-20 EP disclosed
EP-3079685-B1 SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING PAIN BIO PHARM SOLUTIONS CO LTD (KR) 2018-11-28 EP disclosed
EP-3079686-B1 SULFAMATE DERIVATIVE COMPOUND FOR USE IN PREVENTING OR TREATING EPILEPSY BIO PHARM SOLUTIONS CO LTD (KR) 2018-10-24 EP disclosed
US-9937145-B2 Sulfamate derivative compound for use in preventing or treating epilepsy BIO-PHARM SOLUTIONS CO., LTD. (KR) 2018-04-10 US disclosed
US-9834535-B2 Sulfamate derivative compounds for use in treating or alleviating pain BIO-PHARM SOLUTIONS CO., LTD. (KR) 2017-12-05 US disclosed
US-20160310461-A1 Sulfamate Derivative Compound for Use in Preventing or Treating Epilepsy BIO-PHARM SOLUTIONS CO., LTD. (KR) 2016-10-27 US disclosed
EP-3079685-A1 SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING PAIN Bio-Pharm Solutions Co., Ltd. (KR) 2016-10-19 EP disclosed
EP-3079686-A1 SULFAMATE DERIVATIVE COMPOUND FOR USE IN PREVENTING OR TREATING EPILEPSY Bio-Pharm Solutions Co., Ltd. (KR) 2016-10-19 EP disclosed
US-9221783-B2 Phenylalkyl sulfamate compound and muscle relaxant composition comprising the same BIO-PHARM SOLUTIONS CO., LTD. (KR) 2015-12-29 US disclosed
US-20150266848-A1 PHENYLALKYL SULFAMATE COMPOUND AND MUSCLE RELAXANT COMPOSITION COMPRISING THE SAME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2015-09-24 US disclosed
WO-2015088273-A9 SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING PAIN BIO-PHARM SOLUTIONS, CO., LTD. (KR) 2015-08-06 WO disclosed
WO-2015088273-A1 SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING PAIN BIO-PHARM SOLUTIONS, CO., LTD. (KR) 2015-06-18 WO disclosed
WO-2015088271-A1 SULFAMATE DERIVATIVE COMPOUND FOR USE IN PREVENTING OR TREATING EPILEPSY BIO-PHARM SOLUTIONS, CO., LTD. (KR) 2015-06-18 WO disclosed
EP-2861571-A1 PHENYLALKYL SULFAMATE COMPOUND AND MUSCLE RELAXANT COMPOSITION COMPRISING THE SAME Bio-Pharm Solutions Co., Ltd. (KR) 2015-04-22 EP disclosed
WO-2013187727-A1 PHENYLALKYL SULFAMATE COMPOUND AND MUSCLE RELAXANT COMPOSITION COMPRISING THE SAME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2013-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220218702-A1 SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER SLC6A4, SLC6A3, SLC6A2 ACP3 3647/4885ESR1 3809/4885KDM4E 926/4885
US-20150266848-A1 PHENYLALKYL SULFAMATE COMPOUND AND MUSCLE RELAXANT COMPOSITION COMPRISING THE SAME MYLK, MUSK, MYLK2 ACP3 2652/4885ESR1 4812/4885KDM4E 664/4885
US-20160310461-A1 Sulfamate Derivative Compound for Use in Preventing or Treating Epilepsy STS, SULT2A1, GRIK5 ACP3 2532/4885ESR1 3518/4885KDM4E 479/4885
US-11896593-B2 Sulfamate derivative compounds for use in treating or alleviating a psychiatric disorder SLC6A4, SLC6A3, SLC6A2 ACP3 3647/4885ESR1 3809/4885KDM4E 926/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.